Magnesium lactate 84mg modified-release tablets

Background: Evidence regarding the impacts of magnesium (Mg) supplementation on cardiometabolic risk factors (CMRFs) remains inconsistent. Objectives: This systematic review and dose-response meta-analysis evaluated effects of Mg supplementation on anthropometric indices, liver and kidney function, lipid and glycemic profiles, blood pressure, and inflammatory biomarkers. Methods: A systematic search of electronic databases up to May 2026 identified 78 eligible randomized controlled trials. Results: Mg supplementation significantly reduced body weight (weighted mean difference [WMD]: -0.70 kg; 95% confidence interval [CI]: -1.30, -0.09), diastolic blood pressure (WMD: -1.58 mmHg; 95% CI: -2.50, -0.65), homeostasis model assessment of insulin resistance (WMD: -0.48; 95% CI: -0.79, -0.18), low-density lipoprotein cholesterol (WMD: -3.21 mg/dL; 95% CI: -5.27, -1.15), fasting blood glucose (WMD: -3.60 mg/dL; 95% CI: -6.13, -1.06), systolic blood pressure (WMD: -2.50 mmHg; 95% CI: -4.08, -0.91), glycated hemoglobin (WMD: -0.15%; 95% CI: -0.26, -0.03), triglycerides (WMD: -9.24 mg/dL; 95% CI: -16.87, -1.61), and interleukin-6 levels (WMD: -1.10 pg/mL; 95% CI: -1.93, -0.27) compared with controls. High-density lipoprotein cholesterol concentrations significantly increased (WMD: 1.45 mg/dL; 95% CI: 0.37, 2.54). No significant effects were identified on hip circumference, alanine aminotransferase, waist circumference, tumor necrosis factor-α, creatinine, C-reactive protein, body mass index, total cholesterol, fasting insulin, body fat percentage, and aspartate aminotransferase. Most RCTs (79.5%) administered Mg doses ≥ 300 mg/day, and 66.7% had intervention durations ≥ 12 weeks; however, evidence from higher-dose (≥500 mg/day) and longer-term (≥25 weeks) interventions remained limited. Conclusions: Mg supplementation was associated with significant improvements in several CMRFs, including body weight, lipid and glycemic profiles, blood pressure, and interleukin-6 levels. However, these effects were generally modest, and their clinical relevance remains uncertain given the variable certainty of evidence across outcomes.

Abstract licence: CC BY

ObjectivesTo determine whether perioperative IV magnesium sulfate infusion, targeting serum magnesium concentrations of 1.5-2.0 mmol/L, reduces the incidence of postoperative atrial fibrillation (POAF) in patients undergoing cardiac surgery.DesignDouble-blind, randomized, placebo-controlled, single-center clinical trial with interim analysis for futility.SettingHagaZiekenhuis, The Hague, The Netherlands (February 2022-November 2023).PatientsAdult patients undergoing coronary artery bypass grafting and/or valvular surgery without prior atrial arrhythmias or severe renal dysfunction.InterventionsContinuous IV infusion of magnesium sulfate (3 mmol/hr, with bolus if [baseline] magnesium Measurements and main resultsA total of 265 patients underwent randomization before the trial was stopped at interim analysis for futility. Magnesium supplementation achieved clear separation in serum magnesium concentrations between groups. POAF occurred in 50 of 132 patients (37.9%) in the magnesium group and 38 of 133 patients (28.6%) in the placebo group (relative risk, 1.29; 95% CI, 0.92-1.80). No subgroup demonstrated benefit. Time-to-event and day-by-day analyses showed no early reduction in POAF with magnesium. Vasopressor use was more frequent in the magnesium group, although differences were not statistically significant. No safety signal was identified.ConclusionsIn this randomized trial, perioperative magnesium infusion targeting serum concentrations of 1.5-2.0 mmol/L did not reduce POAF after cardiac surgery. These findings do not support routine prophylactic magnesium supplementation for prevention of POAF.

Abstract licence: CC BY-NC-ND

Sepsis remains a major cause of mortality worldwide despite advances in modern critical care. Elevated serum lactate is a key marker of metabolic dysfunction and is strongly associated with adverse outcomes of sepsis. Magnesium plays a crucial role in mitochondrial function, energy production, and cellular metabolism, and its deficiency is frequently observed in critically ill patients with reduced lactate clearance. The recent randomized controlled trial by Anbarasan et al published in World Journal of Critical Care Medicine provided an important evidence that magnesium supplementation enhance lactate clearance, reduced vasopressor requirements, and shortened both intensive care unit and hospital length of stay of septic patients. Their results are quite promising, but have several limitations. The absence of baseline magnesium measurements makes it difficult to determine whether the observed benefits are resulted from correction of hypomagnesemia or from other pharmacological effects of magnesium. Furthermore, the single-center design with relatively small sample size, and the lack of statistically significant mortality benefit limit the generalizationn of the findings. Overall, magnesium supplementation appears to be a promising, safe, and cost-effective adjunctive therapy for sepsis, large multicenter randomized trials and mechanistic studies are required before recommendation for routine clinical use.

Abstract licence: CC BY-NC